235 related articles for article (PubMed ID: 38696048)
1. An overview on liposarcoma subtypes: Genetic alterations and recent advances in therapeutic strategies.
M S A; K C; Bhargavan RV; Somanathan T; Subhadradevi L
J Mol Histol; 2024 Jun; 55(3):227-240. PubMed ID: 38696048
[TBL] [Abstract][Full Text] [Related]
2. Differences in recurrence and survival of extremity liposarcoma subtypes.
Vos M; Koseła-Paterczyk H; Rutkowski P; van Leenders GJLH; Normantowicz M; Lecyk A; Sleijfer S; Verhoef C; Grünhagen DJ
Eur J Surg Oncol; 2018 Sep; 44(9):1391-1397. PubMed ID: 29673808
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the understanding and management of liposarcoma.
Haddox CL; Riedel RF
Fac Rev; 2021; 10():1. PubMed ID: 33659920
[TBL] [Abstract][Full Text] [Related]
4. [Clinical value of fluorescence
Wang W; Li X; Liu P; Dong Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):228-233. PubMed ID: 37042132
[TBL] [Abstract][Full Text] [Related]
5. Influence of age and subtype in outcome of operable liposarcoma.
Greto D; Saieva C; Loi M; Terziani F; Visani L; Garlatti P; Lo Russo M; Muntoni C; Becherini C; Topulli J; Campanacci D; Beltrami G; Scoccianti G; Muratori F; Bonomo P; Desideri I; Francolini G; Livi L
Radiol Med; 2019 Apr; 124(4):290-300. PubMed ID: 30421387
[TBL] [Abstract][Full Text] [Related]
6. Clinical and Molecular Spectrum of Liposarcoma.
Lee ATJ; Thway K; Huang PH; Jones RL
J Clin Oncol; 2018 Jan; 36(2):151-159. PubMed ID: 29220294
[TBL] [Abstract][Full Text] [Related]
7. What's new in adipocytic neoplasia?
Creytens D
Virchows Arch; 2020 Jan; 476(1):29-39. PubMed ID: 31501988
[TBL] [Abstract][Full Text] [Related]
8. Liposarcoma: new entities and evolving concepts.
Dei Tos AP
Ann Diagn Pathol; 2000 Aug; 4(4):252-66. PubMed ID: 10982304
[TBL] [Abstract][Full Text] [Related]
9. Lipidomics and Transcriptomics Differ Liposarcoma Differentiation Characteristics That Can Be Altered by Pentose Phosphate Pathway Intervention.
Song Z; Wang S; Lu L; Xu J; Zhou Q; Lu W; Tong H; Zhang Y; Liu W; Wang Z; Li W; You Y; Zhang C; Guo X; Luo R; Hou Y; Wang C; Wang Y; Sun L; Huang H; Zhou Y
Metabolites; 2022 Dec; 12(12):. PubMed ID: 36557266
[TBL] [Abstract][Full Text] [Related]
10. The utility of fluorescence in situ hybridization (FISH) in determining DNA damage-inducible transcript 3 (DDIT3) amplification in dedifferentiated liposarcomas - an important diagnostic pitfall.
Kuczkiewicz-Siemion O; Wiśniewski P; Dansonka-Mieszkowska A; Grabowska-Kierył M; Olszewska K; Goryń T; Prochorec-Sobieszek M; Rutkowski P; Szumera-Ciećkiewicz A
Pathol Res Pract; 2021 Sep; 225():153555. PubMed ID: 34325315
[TBL] [Abstract][Full Text] [Related]
11. Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma.
Lu J; Wood D; Ingley E; Koks S; Wong D
Mol Biol Rep; 2021 Apr; 48(4):3637-3647. PubMed ID: 33893924
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the 12q amplicons in lipomatous soft tissue tumors by multiplex ligation-dependent probe amplification-based copy number analysis.
Creytens D; Van Gorp J; Speel EJ; Ferdinande L
Anticancer Res; 2015 Apr; 35(4):1835-42. PubMed ID: 25862836
[TBL] [Abstract][Full Text] [Related]
13. Primary Extremity Liposarcoma: MRI Features, Histopathology, and Clinical Outcomes.
Wortman JR; Tirumani SH; Jagannathan JP; Tirumani H; Shinagare AB; Hornick JL; Ramaiya NH
J Comput Assist Tomogr; 2016; 40(5):791-8. PubMed ID: 27224232
[TBL] [Abstract][Full Text] [Related]
14. Increased H3K9me3 drives dedifferentiated phenotype via KLF6 repression in liposarcoma.
Keung EZ; Akdemir KC; Al Sannaa GA; Garnett J; Lev D; Torres KE; Lazar AJ; Rai K; Chin L
J Clin Invest; 2015 Aug; 125(8):2965-78. PubMed ID: 26193637
[TBL] [Abstract][Full Text] [Related]
15. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data.
Binh MB; Sastre-Garau X; Guillou L; de Pinieux G; Terrier P; Lagacé R; Aurias A; Hostein I; Coindre JM
Am J Surg Pathol; 2005 Oct; 29(10):1340-7. PubMed ID: 16160477
[TBL] [Abstract][Full Text] [Related]
16. Expression of the preadipocyte marker ZFP423 is dysregulated between well-differentiated and dedifferentiated liposarcoma.
Dang TN; Tiongco RP; Brown LM; Taylor JL; Lyons JM; Lau FH; Floyd ZE
BMC Cancer; 2022 Mar; 22(1):300. PubMed ID: 35313831
[TBL] [Abstract][Full Text] [Related]
17. Well-differentiated and dedifferentiated liposarcomas.
Coindre JM; Pédeutour F; Aurias A
Virchows Arch; 2010 Feb; 456(2):167-79. PubMed ID: 19688222
[TBL] [Abstract][Full Text] [Related]
18. Dedifferentiated liposarcoma with "homologous" lipoblastic (pleomorphic liposarcoma-like) differentiation: clinicopathologic and molecular analysis of a series suggesting revised diagnostic criteria.
Mariño-Enríquez A; Fletcher CD; Dal Cin P; Hornick JL
Am J Surg Pathol; 2010 Aug; 34(8):1122-31. PubMed ID: 20588177
[TBL] [Abstract][Full Text] [Related]
19. Overview of systemic therapy options in liposarcoma, with a focus on the activity of selinexor, a selective inhibitor of nuclear export in dedifferentiated liposarcoma.
Thirasastr P; Somaiah N
Ther Adv Med Oncol; 2022; 14():17588359221081073. PubMed ID: 35251319
[TBL] [Abstract][Full Text] [Related]
20. Differential diagnosis of atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: utility of p16 in combination with MDM2 and CDK4 immunohistochemistry.
Kammerer-Jacquet SF; Thierry S; Cabillic F; Lannes M; Burtin F; Henno S; Dugay F; Bouzillé G; Rioux-Leclercq N; Belaud-Rotureau MA; Stock N
Hum Pathol; 2017 Jan; 59():34-40. PubMed ID: 27597521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
